
CLAIMS

1. Use of a compound of the formula:



,

or a pharmaceutically acceptable salt or tautomer thereof, in the manufacture of a medicament for treating or preventing chronic kidney disease (CKD) or acute renal injury in a patient in need thereof, wherein the medicament comprises a pharmaceutically effective amount of the compound, and

wherein the patient has been identified as not having at least one of the following characteristics:

(a) a history of left-sided myocardial disease;

(b) an elevated B-type natriuretic peptide (BNP) level; and

(c) an elevated albumin/creatinine ratio (ACR).

2. The use of claim 1 , wherein the patient has been identified as not having at least two of the characteristics.

3. The use of either claim 1 or 2, wherein the patient has been identified as not having all three of the characteristics.

4. The use according to any one of claims 1-3, wherein the patient does not have a history of left-sided myocardial disease.

5. The use according to any one of claims 1-4, wherein the patient does not have an elevated BNP level.

6. The use according to any one of claims 1-5, wherein the patient does not have a BNP level greater than 200 pg/mL.

7. The use according to any one of claims 1-6, wherein the patient does not have an elevated ACR.

8. The use according to any one of claims 1-7, wherein the patient does not have an ACR greater than 300 mg/g.

9. The use according to any one of claims 1-8, wherein the patient's estimated glomerular filtration rate (eGFR) is greater than or equal to 45 mL/min/1.73 m^2.

10. The use according to any one of claims 1-8, wherein the patient's eGFR is greater than or equal to 20 mL/min/1.73 m^2.

11. The use according to any one of claims 1-10, wherein the patient has been identified as having chronic obstructive pulmonary disease (COPD).

12. The use according to any one of claims 1-10, wherein the patient has been identified as not having COPD.

13. The use according to any one of claims 1-12, wherein the patient does not have stage 4 CKD.

14. The use of claim 13, wherein the patient does not have stage 3 or stage 4 CKD.

15. The use of claim 14, wherein the patient does not have stage 2, stage 3, or stage 4 CKD.

16. The use according to any one of claims 1-15, wherein the patient has been identified as having cancer.

17. The use according to any one of claims 1-15, wherein the patient has been identified as not having cancer.

18. The use according to any one of claims 1-17, wherein the patient has been identified as having type 2 diabetes.

19. The use according to any one of claims 1-17, wherein the patient has been identified as not having type 2 diabetes.

20. The use according to any one of claims 1-19, wherein the patient is a human patient.

21. The use according to any one of claims 1-20, wherein at least a portion of the compound is present as a crystalline form having an X-ray diffraction pattern (CuKα) comprising significant diffraction peaks at about 8.8, 12.9, 13.4, 14.2 and 17.4 °2θ.

22. The use of claim 21, wherein the X-ray diffraction pattern (CuKα) is substantially as shown in FIG. 1A or FIG. 1B.

23. The use according to any one of claims 1-20, wherein at least a portion of the compound is present as an amorphous form having an X-ray diffraction pattern (CuKα) with a halo peak at approximately 13.5 °2θ, substantially as shown in FIG. 1C, and a transition glass temperature (T_g).

24. The use of claim 23, wherein the T_g value is in the range of about 120 °C to about 135 °C.

25. The use of claim 24, wherein the T_g value is in the range of about 125 °C to about 130 °C.

26. The use according to any one of claims 1-25, wherein the pharmaceutically effective amount is a daily dose from about 0.1 mg to about 300 mg of the compound.

27. The use of claim 26, wherein the daily dose is from about 2.5 mg to about 30 mg of the compound.

28. The use of claim 27, wherein the daily dose is about 2.5 mg of the compound.

29. The use of claim 27, wherein the daily dose is about 5 mg of the compound.

30. The use of claim 27, wherein the daily dose is about 10 mg of the compound.

31. The use of claim 27, wherein the daily dose is about 20 mg of the compound.

32. The use of claim 27, wherein the daily dose is about 30 mg of the compound.

33. The use according to any one of claims 1-32, wherein the medicament is formulated for administration orally, intraarterially or intravenously.

34. The use according to any one of claims 1-33, wherein the medicament is formulated as a solid dispersion comprising (i) the compound and (ii) an excipient.

35. The use of claim 34, wherein the excipient is a methacrylic acid – ethyl acrylate copolymer.

36. The use of claim 35, wherein the copolymer comprises methacrylic acid and ethyl acrylate at a 1:1 ratio.